Yuzo Shimazu

Fukushima, 9601295, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection.

Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection.

Journal: Science translational medicine

Published: September 17, 2025

Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey.

Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey.

Journal: Vaccine: X

Published: May 24, 2024

Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan.

Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan.

Journal: Vaccines

Published: April 03, 2023

Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination.

Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination.

Journal: Scientific reports

Published: February 27, 2023

Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population.

Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population.

Journal: PLOS digital health

Published: February 02, 2023

Smoking cessation treatment by anesthesiologists.

Smoking cessation treatment by anesthesiologists.

Journal: Journal of anesthesia

Published: November 11, 2022

Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima.

Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima.

Journal: Vaccines

Published: October 23, 2022

Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years and comparison with individuals aged 12-15 years: an observational and historical cohort study.

Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years and comparison with individuals aged 12-15 years: an observational and historical cohort study.

Journal: European journal of pediatrics

Published: August 04, 2022

Maturing of public-private-people partnership (4P): Lessons from 4P for triple disaster and subsequently COVID-19 pandemic in Fukushima.

Maturing of public-private-people partnership (4P): Lessons from 4P for triple disaster and subsequently COVID-19 pandemic in Fukushima.

Journal: Journal of global health

Published: June 08, 2022

A retrospective observational study analyzing work and study motivation based on the work environment of 15,677 Japanese clinicians in 2016.

A retrospective observational study analyzing work and study motivation based on the work environment of 15,677 Japanese clinicians in 2016.

Journal: Scientific reports

Published: May 12, 2022

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey.

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey.

Journal: Scientific reports

Published: March 01, 2022

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine.

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine.

Journal: Fukushima journal of medical science

Published: March 01, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026